Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTO1 in Pediatric R/R B-ALL and B-NHL
NCT06173518Phase 1Recruiting
- Sponsor
- Autolus Therapeutics plc
- Start
- Nov 2023
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of obecabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma, sponsored by Autolus Therapeutics plc. Primary endpoints: Frequency and severity of adverse events and serious adverse events at 24 months, Incidence and duration of severe hypogammaglobulinemia at 24 months and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
obecabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06173518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173518.